MX2009000975A - Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. - Google Patents

Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos.

Info

Publication number
MX2009000975A
MX2009000975A MX2009000975A MX2009000975A MX2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A MX 2009000975 A MX2009000975 A MX 2009000975A
Authority
MX
Mexico
Prior art keywords
inflammatory mediators
methods
present
release
inhibiting
Prior art date
Application number
MX2009000975A
Other languages
English (en)
Inventor
Indu Parikh
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of MX2009000975A publication Critical patent/MX2009000975A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención incluye métodos para inhibir o suprimir los procesos secretores celulares. Más en específico, la presente invención se refiere a la inhibición o reducción de la liberación de mediadores inflamatorios desde células inflamatorias, inhibiendo el mecanismo asociado con la liberación de mediadores inflamatorios desde los gránulos de las células inflamatorias. En este sentido, la presente invención describe un mecanismo señalizador intracelular que ilustra varios blancos intracelulares novedosos para intervención farmacológica, en trastornos que implican la secreción de mediadores inflamatorios desde las vesículas de las células inflamatorias. Los fragmentos de péptido y sus variantes del péptido MANS, que están descritos en la presente invención, son útiles en esos métodos.
MX2009000975A 2006-07-26 2007-07-26 Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos. MX2009000975A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83323906P 2006-07-26 2006-07-26
PCT/US2007/074514 WO2008014414A2 (en) 2006-07-26 2007-07-26 Methods for attenuating release of inflammatory mediators and peptides useful therein

Publications (1)

Publication Number Publication Date
MX2009000975A true MX2009000975A (es) 2009-04-07

Family

ID=38982357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000975A MX2009000975A (es) 2006-07-26 2007-07-26 Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos.

Country Status (22)

Country Link
US (6) US8999915B2 (es)
EP (2) EP2053915B1 (es)
JP (2) JP5378998B2 (es)
KR (1) KR101599894B1 (es)
CN (2) CN103990111B (es)
AU (1) AU2007279193B2 (es)
BR (1) BRPI0714953A2 (es)
CA (2) CA2658949C (es)
DK (2) DK2053915T3 (es)
ES (2) ES2725599T3 (es)
HK (2) HK1125793A1 (es)
HR (1) HRP20140587T1 (es)
IL (1) IL196667A (es)
MX (1) MX2009000975A (es)
NO (1) NO20090304L (es)
PL (2) PL2053915T3 (es)
PT (1) PT2053915E (es)
RU (1) RU2423376C2 (es)
SG (2) SG173411A1 (es)
SI (1) SI2053915T1 (es)
WO (1) WO2008014414A2 (es)
ZA (1) ZA200900550B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101146545B (zh) 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
CA2766157A1 (en) * 2009-06-25 2010-12-29 Hua Gong Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) * 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
ES2714863T3 (es) 2013-04-05 2019-05-30 Biomarck Pharmaceuticals Ltd Péptidos del inhibidor de MARCKS para la inhibición de metástasis
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
WO2015095789A2 (en) 2013-12-20 2015-06-25 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) * 2019-02-20 2020-11-20 한국외국어대학교 연구산학협력단 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
WO2023212443A1 (en) * 2022-04-25 2023-11-02 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating skin diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61265341A (ja) * 1985-05-17 1986-11-25 Kawasaki Heavy Ind Ltd Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
WO1995027496A1 (en) 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
DE60014856T2 (de) * 1999-02-24 2006-02-02 North Carolina State University Zusammensetzungen zur modulierung der schleimsekretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
DK1104758T3 (da) 1999-12-03 2003-10-20 Pfizer Prod Inc Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
ATE519493T1 (de) 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
JP2004049133A (ja) 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
CN101146545B (zh) 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽

Also Published As

Publication number Publication date
CA2658949A1 (en) 2008-01-31
PL2722052T3 (pl) 2019-08-30
WO2008014414A3 (en) 2008-09-25
SG10201500418QA (en) 2015-03-30
US8999915B2 (en) 2015-04-07
CA2842219C (en) 2017-07-11
CN103990111B (zh) 2016-08-31
CN101516190B (zh) 2014-06-11
JP5819889B2 (ja) 2015-11-24
EP2053915A4 (en) 2011-06-08
EP2053915A2 (en) 2009-05-06
KR20090037487A (ko) 2009-04-15
US20090203620A1 (en) 2009-08-13
RU2423376C2 (ru) 2011-07-10
PT2053915E (pt) 2014-08-25
CA2842219A1 (en) 2008-01-31
JP2009544737A (ja) 2009-12-17
IL196667A (en) 2017-04-30
HRP20140587T1 (hr) 2014-11-21
EP2722052B1 (en) 2019-03-20
SG173411A1 (en) 2011-08-29
HK1125793A1 (en) 2009-08-21
US20230293629A1 (en) 2023-09-21
US9827287B2 (en) 2017-11-28
ES2725599T3 (es) 2019-09-25
HK1201190A1 (en) 2015-08-28
SI2053915T1 (sl) 2014-10-30
CA2658949C (en) 2014-04-22
US20180036367A1 (en) 2018-02-08
ZA200900550B (en) 2010-03-31
AU2007279193A1 (en) 2008-01-31
CN101516190A (zh) 2009-08-26
RU2009106673A (ru) 2010-09-10
US20160030509A1 (en) 2016-02-04
KR101599894B1 (ko) 2016-03-04
BRPI0714953A2 (pt) 2013-07-16
PL2053915T3 (pl) 2014-12-31
ES2488092T3 (es) 2014-08-26
JP5378998B2 (ja) 2013-12-25
EP2722052A1 (en) 2014-04-23
JP2013241428A (ja) 2013-12-05
EP2053915B1 (en) 2014-06-11
CN103990111A (zh) 2014-08-20
DK2722052T3 (en) 2019-04-29
US20210260154A1 (en) 2021-08-26
IL196667A0 (en) 2011-08-01
US20200138898A1 (en) 2020-05-07
NO20090304L (no) 2009-04-21
AU2007279193B2 (en) 2011-12-01
DK2053915T3 (da) 2014-06-30
WO2008014414A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2007103368A3 (en) Methods for regulating inflammatory mediators and peptides useful therein
MX2009000975A (es) Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2007120842A3 (en) Methods and compositions for targeting c-rel
MY171289A (en) Inhibitors of e1 activating enzymes
MX2009001309A (es) Compuestos de heteroarilo utiles como inhibidores de enzimas de activacion e1.
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2007054623A3 (en) Mammalian hedgehog signaling inhiabitors
EP2185197A4 (en) NOVEL COMPOSITIONS OF A SOLUTION CONTAINING A CELLULAR FACTOR
WO2010129917A3 (en) Anti-cd100 antibodies and methods for using the same
WO2006116381A3 (en) Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
WO2008030612A3 (en) Site specific incorporation of non-natural amino acids by vertebrate cells
WO2011004028A3 (en) Tlr3 binding agents
WO2007084419A3 (en) Inhibition of inflammatory cytokine production with tanshinones
WO2005117557A3 (en) Expression system
WO2008011071A3 (en) Interactions of hedgehog and liver x receptor signaling pathways
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2010144231A3 (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
EP1971608A4 (en) spiroketals

Legal Events

Date Code Title Description
FG Grant or registration